<p>SPC (green) and GlcSph (blue) for the age range 0–50 years with miglustat-naïve NP-C patients compared to the control group. The area under the curve (95% CI) was 0.9994 (0.9972 to 1.002) and 0.7764 (0.6479 to 0.9048) for SPC and GlcSph respectively.</p
<p>Using a cut-off point of 83 ng/ml ROC analysis revealed an area under curve (AUC) of 0.968 (p<0.0...
<p>The area under the ROC curve for C22-Cer was 0.814 and for C24:1-Cer it was 0.729. AUC- Area unde...
<p>ROC curves determined thresholds for establishing positive test values. Phospho-RB is expressed a...
<p>One sample per patient is shown, where multiple samples from one patient were available the first...
<p>The control subjects are black circles, the NP-C patients are colored by miglustat treatment stat...
<p>CRC cases vs. healthy subjects. A. All cancers vs. healthy subjects in the 2nd set. B. Lung cance...
<p>CRC cases vs. healthy subjects. A. All cancer cases vs. healthy subjects in the second set. B. Lu...
<p>A. Serum MIC-1 concentrations in GC patients (median = 1372 pg/ml) and controls (median = 351 p...
ROC curves at 30% and 70% G6PD activity thresholds on A) capillary specimens and B) venous specimens...
<p>(a) SROC for SPG in the diagnosis of GC; (b) SROC for SPG in the diagnosis of AG.</p
<p>Patient distributions are shown in (a-d). The Kruskal-Wallis test was performed followed by Dunn’...
<p>Fig 4 shows the ROC curves generated for the sCD163 ratio (4a), the CXCL13 ratio (4b), the NEO ra...
<p>A) Correlation between the plasma levels of VS-1 and total-CgA in patients with NENs (solid circl...
<p>Fig 5 shows the combined ROC curves generated for the IgG index and the sCD163 ratio (5a), the CX...
<p>(a) ROC analyses for CA125 and LRG1 to differentiate EOC from healthy controls. (b) ROC analyses ...
<p>Using a cut-off point of 83 ng/ml ROC analysis revealed an area under curve (AUC) of 0.968 (p<0.0...
<p>The area under the ROC curve for C22-Cer was 0.814 and for C24:1-Cer it was 0.729. AUC- Area unde...
<p>ROC curves determined thresholds for establishing positive test values. Phospho-RB is expressed a...
<p>One sample per patient is shown, where multiple samples from one patient were available the first...
<p>The control subjects are black circles, the NP-C patients are colored by miglustat treatment stat...
<p>CRC cases vs. healthy subjects. A. All cancers vs. healthy subjects in the 2nd set. B. Lung cance...
<p>CRC cases vs. healthy subjects. A. All cancer cases vs. healthy subjects in the second set. B. Lu...
<p>A. Serum MIC-1 concentrations in GC patients (median = 1372 pg/ml) and controls (median = 351 p...
ROC curves at 30% and 70% G6PD activity thresholds on A) capillary specimens and B) venous specimens...
<p>(a) SROC for SPG in the diagnosis of GC; (b) SROC for SPG in the diagnosis of AG.</p
<p>Patient distributions are shown in (a-d). The Kruskal-Wallis test was performed followed by Dunn’...
<p>Fig 4 shows the ROC curves generated for the sCD163 ratio (4a), the CXCL13 ratio (4b), the NEO ra...
<p>A) Correlation between the plasma levels of VS-1 and total-CgA in patients with NENs (solid circl...
<p>Fig 5 shows the combined ROC curves generated for the IgG index and the sCD163 ratio (5a), the CX...
<p>(a) ROC analyses for CA125 and LRG1 to differentiate EOC from healthy controls. (b) ROC analyses ...
<p>Using a cut-off point of 83 ng/ml ROC analysis revealed an area under curve (AUC) of 0.968 (p<0.0...
<p>The area under the ROC curve for C22-Cer was 0.814 and for C24:1-Cer it was 0.729. AUC- Area unde...
<p>ROC curves determined thresholds for establishing positive test values. Phospho-RB is expressed a...